TScan Therapeutics, Inc. (TCRX) News
Track canonical SquawkNews coverage tagged to TCRX, TScan Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
TScan Therapeutics cut to Neutral from Buy by HC Wainwright
HC Wainwright & Co. downgraded TScan Therapeutics to Neutral from Buy, according to Benzinga ratings actions cited by TradingView News.
EQUITY | Sep 08, 2026, 03:25 PM UTC
L
TScan Therapeutics price target cut to $1.00 from $5.00
Wedbush cut its price target on TScan Therapeutics to $1.00 per share from $5.00, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 01:19 PM UTC
L
TScan Therapeutics cut to Hold from Buy by Needham
Needham downgraded TScan Therapeutics to Hold from Buy, per Benzinga ratings actions.
EQUITY | Sep 03, 2026, 09:16 AM UTC
M
U.S. factory orders rise 0.9% in July, topping estimates
U.S. factory orders rose 0.9% month-over-month in July, compared with estimates for a 0.7% gain.
MACRO | Sep 02, 2026, 04:01 PM UTC
M
TCRX in vivo TCR therapies move to IND-enabling stage
TCRX says two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities. Preclinical data and regulatory updates are expected in Q1 2027, with a phase I trial planned for Q4 2027.
EQUITY | Sep 02, 2026, 02:39 PM UTC
M
TCRX advances solid-tumor TCR programs to IND-enabling stage
TCRX said two in vivo solid-tumor TCR therapies (PRAME, MAGE-A4) moved to IND-enabling stage with clinical trials planned for late 2027. Heme and autoimmune efforts are paused; financial runway extended into Q4 2027.
EQUITY | Sep 02, 2026, 01:38 PM UTC
M
TCRX TSC-101 reports 79% 6-month relapse-free survival in post-HCT
TSC-101 in high-risk post-HCT patients showed 79% relapse-free survival at 6 months, with safety also reported in the heme program.
EQUITY | Sep 02, 2026, 11:58 AM UTC
L
TScan terminates CFO and CMO in strategic reorganization
TScan terminated CFO Jason A. Amello and CMO Chrystal Louis as part of a strategic reorganization, and CEO Gavin MacBeath assumed principal financial and accounting officer duties effective September 2, 2026.
REGULATION | Sep 02, 2026, 11:24 AM UTC
L
TScan Therapeutics gets Nasdaq notice over $1 minimum bid
Nasdaq notified the company that its common stock failed the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1) for 30 consecutive trading days. Trading continues on Nasdaq Global Market; 180 days to Feb.
EQUITY | Sep 02, 2026, 11:24 AM UTC
M
TCRX shifts focus to in vivo TCR-T solid tumor programs
TCRX says a reorganization will advance two in vivo TCR-T solid tumor candidates to IND-enabling studies and plan Phase 1 trials in late 2027, while pausing or seeking partners for heme malignancy and autoimmune programs
EQUITY | Sep 02, 2026, 11:13 AM UTC
L
TScan Therapeutics announces reorganization to focus on solid-tumor cell therapy
TScan Therapeutics says it will reorganize to focus on in vivo cell therapy for solid tumors.
EQUITY | Sep 02, 2026, 11:02 AM UTC
L
TCRX Reports Q2 2026 Financial Results
TScan Therapeutics reports second quarter 2026 financial results and provides corporate update
EARNINGS | Aug 12, 2026, 11:00 AM UTC
H
TCRX doses first patient
TScan starts Phase 3 trial
EQUITY | Jul 29, 2026, 11:01 AM UTC
M
TCRX: Moves to Phase 3
TScan's cancer therapy data supports move to Phase 3 trial
EQUITY | Jun 22, 2026, 11:10 AM UTC
H
TCRX: Reports Positive Data
TScan Therapeutics announces positive initial data from cohort C of ongoing ALLOHA Phase 1 study evaluating TSC-101
EQUITY | Jun 22, 2026, 11:00 AM UTC